The 2023 Windsor Framework reshaped how medicines reach Northern Ireland. One of its practical products is the Northern Ireland MHRA Authorised Route — NIMAR for short. NIMAR is the mechanism that keeps specific UK-licensed human medicines flowing from Great Britain to community, hospital and specialist pharmacies in Northern Ireland when those products would not otherwise hold an NI marketing authorisation.
For community pharmacy in England, Scotland and Wales, NIMAR rarely matters day-to-day. For community pharmacy in Northern Ireland, it is structural — it keeps specific prescriptions dispensable. This piece explains what NIMAR is, how a product gets on the list, and how the supply chain works.
The problem NIMAR solves
Before the Windsor Framework, the risk was that medicines licensed in Great Britain through the MHRA alone — without a separate European Medicines Agency (EMA) authorisation — would be ineligible for routine placement on the Northern Irish market because of EU single-market pharmaceutical rules applied through the Northern Ireland Protocol. For some products this would have required either a second, separate NI-specific marketing authorisation or a parallel EMA licence. For manufacturers of low-volume or older UK-specific medicines, neither was commercially realistic, and NI patients would have lost supply.
The Windsor Framework introduced a UK-wide licensing approach for medicines destined for the NHS across the whole of the UK. NIMAR is the operational list that sits underneath it.
How NIMAR works in practice
NIMAR is an authorised-listing mechanism run by DHSC and the MHRA. Products added to the NIMAR list may be supplied from a UK (pre-Windsor: Great Britain) manufacturing authorisation holder to licensed wholesalers in Northern Ireland, and from those wholesalers to NI community and hospital pharmacy.
Three points matter for community pharmacy:
- A NIMAR-listed product reaches the NI dispensing counter through the normal wholesale channel (AAH, Phoenix, Alliance Healthcare and the Northern Ireland specialist wholesalers). There is no separate prescription endorsement.
- A NIMAR listing does not change dispensing rules. The medicine is dispensed against an NHS prescription in the normal way.
- The list is revised. Products can be added and removed. DHSC and MHRA publish revisions periodically.
What kinds of medicines appear on NIMAR
The list is weighted toward:
- Older, generic UK-specific medicines without an EU-wide licence.
- Low-volume specialist medicines where a second authorisation is uneconomic.
- Medicines where the UK is the sole or primary market.
It is not a mechanism for introducing unlicensed medicines. Every NIMAR-listed product is a UK-licensed medicine. The route is about market access across the UK, not licensing standards.
What NIMAR is not
NIMAR is often confused with three other mechanisms:
Specials and unlicensed imports. These remain governed by MHRA's specials regulation and the prescriber's clinical responsibility. NIMAR medicines are UK-licensed; specials are not.
Parallel imports. Parallel importation of EU-licensed medicines into GB continues under its own rules. NIMAR is a different pathway.
The Serious Shortage Protocol (SSP). SSPs are temporary NHS-level tools used when a nationwide shortage requires a structured alternative supply. A NIMAR medicine can still be subject to an SSP if it goes short; the mechanisms are independent.
Checking the current list
DHSC and MHRA maintain and publish the NIMAR list online. Community pharmacy teams in NI supplying an unfamiliar product should check the latest published list rather than relying on distributor confirmation alone. The list is the source of truth.
Prescribers in Great Britain writing for NI patients
A prescription written in Great Britain for an NI-resident patient is normally filled in NI by an NI-registered community pharmacy. Cross-border dispensing rules have not changed in a way that a typical community prescriber needs to worry about. Medicines on NIMAR are available through the same wholesale and prescribing pathway as all other UK medicines.
Practical implications for NI community pharmacy
| Situation | Action |
|---|---|
| Prescription for a UK-licensed medicine that has always been routinely stocked | Dispense as normal — likely NIMAR-covered if relevant |
| Wholesaler flags supply restriction on a product you've long dispensed | Check current NIMAR list and wholesaler notes for clarification |
| Request for an unlicensed medicine | Unlicensed specials pathway applies — NIMAR does not cover this |
| Prescription for a licensed medicine that has suddenly become unavailable | Check for an active SSP before substituting |
Broader sector context
Community pharmacy workload pressures across the UK are well documented. PharmSee's public-jobs-feed tracker captured 1,651 live UK pharmacy vacancies across eleven sources on 14 April 2026. NIMAR does not by itself affect workload, but a change in supply pathway or a list revision can surface through unexpected wholesale conversations on any given day — which is why a rough mental model of the mechanism is useful even if you rarely think about it.
Caveats
This article describes NIMAR at the time of publication. The list, the supporting guidance and the Windsor Framework's implementation continue to evolve. Always work from current DHSC and MHRA-published guidance for specific products and supply questions.
Sources
- DHSC / MHRA published guidance on the Northern Ireland MHRA Authorised Route.
- UK Government: implementation of the Windsor Framework.
- Current NIMAR listing as maintained by DHSC and MHRA.